X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs GSK PHARMA - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA GSK PHARMA SUN PHARMA/
GSK PHARMA
 
P/E (TTM) x 27.2 53.7 50.8% View Chart
P/BV x 2.9 10.6 27.0% View Chart
Dividend Yield % 0.4 2.7 16.2%  

Financials

 SUN PHARMA   GSK PHARMA
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
GSK PHARMA
Mar-18
SUN PHARMA/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs7012,760 25.4%   
Low Rs4332,040 21.2%   
Sales per share (Unadj.) Rs110.4339.0 32.6%  
Earnings per share (Unadj.) Rs11.041.4 26.5%  
Cash flow per share (Unadj.) Rs17.245.9 37.5%  
Dividends per share (Unadj.) Rs2.0035.00 5.7%  
Dividend yield (eoy) %0.41.5 24.2%  
Book value per share (Unadj.) Rs158.8242.9 65.4%  
Shares outstanding (eoy) m2,399.2684.70 2,832.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.17.1 72.5%   
Avg P/E ratio x51.657.9 89.1%  
P/CF ratio (eoy) x32.952.3 62.9%  
Price / Book Value ratio x3.69.9 36.1%  
Dividend payout %18.284.5 21.6%   
Avg Mkt Cap Rs m1,360,021203,280 669.0%   
No. of employees `00017.8NA-   
Total wages/salary Rs m53,6715,234 1,025.4%   
Avg. sales/employee Rs Th14,890.9NM-  
Avg. wages/employee Rs Th3,017.1NM-  
Avg. net profit/employee Rs Th1,480.6NM-  
INCOME DATA
Net Sales Rs m264,89528,715 922.5%  
Other income Rs m8,388545 1,537.8%   
Total revenues Rs m273,28229,260 934.0%   
Gross profit Rs m56,0815,059 1,108.6%  
Depreciation Rs m14,998380 3,946.9%   
Interest Rs m5,1762 258,785.0%   
Profit before tax Rs m44,2955,222 848.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-9,505178 -5,339.9%   
Tax Rs m8,4521,892 446.7%   
Profit after tax Rs m26,3383,508 750.8%  
Gross profit margin %21.217.6 120.2%  
Effective tax rate %19.136.2 52.7%   
Net profit margin %9.912.2 81.4%  
BALANCE SHEET DATA
Current assets Rs m316,35921,815 1,450.2%   
Current liabilities Rs m198,64315,999 1,241.6%   
Net working cap to sales %44.420.3 219.4%  
Current ratio x1.61.4 116.8%  
Inventory Days Days9564 149.1%  
Debtors Days Days10819 576.3%  
Net fixed assets Rs m213,17812,475 1,708.9%   
Share capital Rs m2,399847 283.3%   
"Free" reserves Rs m378,60619,726 1,919.3%   
Net worth Rs m381,00620,573 1,851.9%   
Long term debt Rs m17,7216 295,348.3%   
Total assets Rs m643,02839,475 1,629.0%  
Interest coverage x9.62,612.0 0.4%   
Debt to equity ratio x00 15,948.0%  
Sales to assets ratio x0.40.7 56.6%   
Return on assets %4.98.9 55.1%  
Return on equity %6.917.1 40.5%  
Return on capital %10.026.2 38.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m40,816564 7,237.0%   
Fx outflow Rs m30,1437,429 405.8%   
Net fx Rs m10,673-6,865 -155.5%   
CASH FLOW
From Operations Rs m39,0724,728 826.4%  
From Investments Rs m-33,708-1,042 3,235.3%  
From Financial Activity Rs m-15,393-3,066 502.0%  
Net Cashflow Rs m-7,359620 -1,187.5%  

Share Holding

Indian Promoters % 63.7 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 5.1 10.2 50.3%  
FIIs % 23.0 23.8 96.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 15.4 53.9%  
Shareholders   133,026 102,036 130.4%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   CADILA HEALTHCARE  TTK HEALTHCARE  ORCHID PHARMA LTD  BIOCON   J.B.CHEMICALS  

Compare SUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Downtrend; Sensex Ends 495 Points Lower(Closing)

Indian share markets witnessed most of the selling pressure during closing hours and ended their trading session on a negative note.

Related Views on News

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 26.0% (Quarterly Result Update)

Feb 5, 2019 | Updated on Feb 5, 2019

For the quarter ended December 2018, GSK PHARMA has posted a net profit of Rs 1 bn (up 26.0% YoY). Sales on the other hand came in at Rs 8 bn (up 17.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 22.7% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 22.7% YoY). Sales on the other hand came in at Rs 8 bn (down 2.4% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

Stocks that Could Be Out of Reach Post Elections(The 5 Minute Wrapup)

Apr 9, 2019

It's a matter of time before the stocks catch the fancy of the markets and big investors.

3 Indian Stocks with Amazon-Like Potential(Profit Hunter)

Apr 10, 2019

We have identified 3 stocks with huge wealth building potential which meet our 'Click of a Button' criteria.

This Company is Making a Big Comeback and You Can Now Profit from Its Example(The 5 Minute Wrapup)

Apr 10, 2019

How Dell got its mojo back.

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Apr 22, 2019 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS